SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Robohogs who wrote (9949)2/21/2007 10:16:53 AM
From: Iamarangerboy  Respond to of 10280
 
Press Release Source: Sepracor Inc.

Sepracor Announces Publication of Additional Data from Lunesta(R) Insomnia-Depression Study in the Journal of Clinical Sleep Medicine
Wednesday February 21, 7:00 am ET

biz.yahoo.com

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR - News) today announced that additional data from its Phase IIIB/IV, 545-patient study of LUNESTA® brand eszopiclone in patients with insomnia and co-existing major depressive disorder (MDD) have been published in the February 2007 edition of the Journal of Clinical Sleep Medicine. This manuscript contains results from the two-week, single-blind, placebo run-out period of the study that evaluated hypnotic discontinuation effects following an eight-week, placebo-controlled study of LUNESTA and PROZAC® brand fluoxetine co-therapy in patients with insomnia and co-existing MDD.



To: Robohogs who wrote (9949)2/27/2007 11:59:23 AM
From: Rocky9  Read Replies (2) | Respond to of 10280
 
Lunesta 134,854
MDI 48,314